应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SGEN Seagen
停牌 12-13 16:00:00 EST
228.74
+0.00
0.00%
最高
228.74
最低
228.74
成交量
0.00
今开
228.74
昨收
228.74
日振幅
0.00%
总市值
431.55亿
流通市值
296.98亿
总股本
1.89亿
成交额
45.94亿
换手率
0.00%
流通股本
1.30亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
ETF追踪 | 生物科技行业2024:交易激增、创新迎来曙光
ETF小帮手 · 2023-12-31
ETF追踪 | 生物科技行业2024:交易激增、创新迎来曙光
和铂医药(02142)高开近12% 宣布与Seagen Inc.就HBM9033签订许可协议
凤凰网港股 · 2023-12-15
和铂医药(02142)高开近12% 宣布与Seagen Inc.就HBM9033签订许可协议
和铂医药-B(02142)与Seagen Inc.就HBM9033签订许可协议
智通财经 · 2023-12-15
和铂医药-B(02142)与Seagen Inc.就HBM9033签订许可协议
辉瑞完成对Seagen的收购
老虎资讯综合 · 2023-12-14
辉瑞完成对Seagen的收购
辉瑞宣布已完成对生物科技公司Seagen的收购
国际金融报 · 2023-12-14
辉瑞宣布已完成对生物科技公司Seagen的收购
辉瑞获批完成收购生物技术公司Seagen
老虎资讯综合 · 2023-12-12
辉瑞获批完成收购生物技术公司Seagen
这个投资组合2023年回报率31%远超大盘,有什么秘密?
金融界 · 2023-11-25
这个投资组合2023年回报率31%远超大盘,有什么秘密?
辉瑞(PFE.US)CEO:非常渴望与Seagen(SGEN.US)合作
智通财经 · 2023-11-01
辉瑞(PFE.US)CEO:非常渴望与Seagen(SGEN.US)合作
辉瑞430亿美元收购Seagen获欧盟无条件批准
智通财经 · 2023-10-20
辉瑞430亿美元收购Seagen获欧盟无条件批准
加载更多
公司概况
公司名称:
Seagen
所属市场:
NASDAQ
上市日期:
--
主营业务:
Seagen Inc.于1997年7月15日在特拉华州成立。该公司是一家全球性生物技术公司,致力于发现,开发和商业化可转化的癌症药物,从而对人们的生活产生重大影响。公司总部位于华盛顿州西雅图市,并在加利福尼亚,加拿大,瑞士和欧盟设有分支机构。
发行价格:
--
{"stockData":{"symbol":"SGEN","market":"US","secType":"STK","nameCN":"Seagen","latestPrice":228.74,"timestamp":1702501200000,"preClose":228.74,"halted":3,"volume":0,"delay":0,"floatShares":129833047,"shares":188662672,"eps":-4.008131,"marketStatus":"停牌","marketStatusCode":7,"change":0,"latestTime":"12-13 16:00:00 EST","open":228.74,"high":228.74,"low":228.74,"amount":4593823996.75067,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.008131,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1711958400000},"adr":0,"adjPreClose":228.74,"adrRate":0,"volumeRatio":0},"requestUrl":"/m/hq/s/SGEN","defaultTab":"news","newsList":[{"id":"1185510638","title":"ETF追踪 | 生物科技行业2024:交易激增、创新迎来曙光","url":"https://stock-news.laohu8.com/highlight/detail?id=1185510638","media":"ETF小帮手","top":-1,"share":"https://www.laohu8.com/m/news/1185510638?lang=zh_cn&edition=full","pubTime":"2023-12-31 20:11","pubTimestamp":1704024683,"startTime":"0","endTime":"0","summary":"生物科技行业正在迎来复苏,摆脱了一段时间的低迷。展望2024年,分析师们预计更有利的利率环境、交易活动的增加,以及在癌症和免疫学等关键领域的创新将为生物技术公司带来更为光明的前景。自10月底以来,生物科技行业的指数已经上涨了29%。这两个行业在截至2023年12月28日的12个月内共进行了超2220亿美元的并购交易。该 ETF 目前拥有约 275 只生物科技股票。ETF 通常持有 40 至 60 只股票。方舟基因革命ETF于2014年开始交易。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2391353896","title":"和铂医药(02142)高开近12% 宣布与Seagen Inc.就HBM9033签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2391353896","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2391353896?lang=zh_cn&edition=full","pubTime":"2023-12-15 09:31","pubTimestamp":1702603872,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和铂医药 延续此前上涨趋势,今日高开近12%,报1.98港元。该股本周涨幅势将超过50%。和铂医药公布,公司全资子公司诺纳生物(苏州)与辉瑞旗下的Seagen Inc.,已就HBM9033的全球临床开发及商业化订立许可协议。根据协议,诺纳生物将收取总额为5300万美元的预付款及近期付款;基于若干待达成的开发及商业化成果计算的潜在里程碑付款,总额可高达约10.5亿美元;及按净销售额支付的分级特许权使用费,最高比例可达高双位数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=8108143c8f6bf78429cb545e8c5e5d5d","is_publish_highlight":false,"gpt_icon":0},{"id":"2391682191","title":"和铂医药-B(02142)与Seagen Inc.就HBM9033签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2391682191","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2391682191?lang=zh_cn&edition=full","pubTime":"2023-12-15 07:41","pubTimestamp":1702597294,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和铂医药-B 公布,公司全资子公司诺纳生物(苏州)有限公司与Seagen Inc.已就HBM9033的全球临床开发及商业化订立许可协议。基于上文所述,董事会认为签订协议符合公司及其股东的整体最佳利益。独特的抗体设计使其在各种具有不同MSLN表达水平的临床前肿瘤模型研究中展现出卓越的疗效和安全性,从而使HBM9033成为潜在的全球同类最佳治疗方案。辉瑞已取得必要的监管批准,并于2023年12月14日完成对Seagen的收购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231215074437825641e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231215074437825641e9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"1137353661","title":"辉瑞完成对Seagen的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1137353661","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1137353661?lang=zh_cn&edition=full","pubTime":"2023-12-14 21:06","pubTimestamp":1702559204,"startTime":"0","endTime":"0","summary":"12月14日,$辉瑞(PFE)$公司宣布成功完成对癌症制药商$Seagen(SGEN)$的收购。辉瑞以每股229美元的现金完成了对Seagen所有流通普通股的收购,企业总价值约430亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2391574458","title":"辉瑞宣布已完成对生物科技公司Seagen的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2391574458","media":"国际金融报","top":-1,"share":"https://www.laohu8.com/m/news/2391574458?lang=zh_cn&edition=full","pubTime":"2023-12-14 21:01","pubTimestamp":1702558918,"startTime":"0","endTime":"0","summary":"辉瑞宣布已完成对生物科技公司Seagen的收购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231214210202790172df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231214210202790172df&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"1133552925","title":"辉瑞获批完成收购生物技术公司Seagen","url":"https://stock-news.laohu8.com/highlight/detail?id=1133552925","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1133552925?lang=zh_cn&edition=full","pubTime":"2023-12-12 19:48","pubTimestamp":1702381697,"startTime":"0","endTime":"0","summary":"12月12日,$辉瑞(PFE)$获得完成收购生物技术公司$Seagen(SGEN)$所需的批准,预计于12月14日完成收购,新组织架构将于1月1日生效。受此消息影响,Seagen美股盘前直线拉升,现涨逾3%。","market":"us","thumbnail":"https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2386950925","title":"这个投资组合2023年回报率31%远超大盘,有什么秘密?","url":"https://stock-news.laohu8.com/highlight/detail?id=2386950925","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2386950925?lang=zh_cn&edition=full","pubTime":"2023-11-25 05:04","pubTimestamp":1700859873,"startTime":"0","endTime":"0","summary":"根据高盛的数据,对冲基金最喜欢的股票在 2023 年压倒了大盘,回报率达到 31%,这要归功于超大市值的科技公司。根据监管文件,这家华尔街银行分析了 735 家对冲基金的持股情况,这些基金在第四季度初持有 2.4 万亿美元的股票多头和空头头寸。VIP 股票在 2023 年的标普 500 指数涨幅为 18%,延续了长期以来战胜市场的历史。这些科技巨头全年一直领跑市场,其中Meta在2023年飙升了181%,微软今年上涨了55%,亚马逊上涨了70%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/25050438566627.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2380630559","title":"辉瑞(PFE.US)CEO:非常渴望与Seagen(SGEN.US)合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2380630559","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2380630559?lang=zh_cn&edition=full","pubTime":"2023-11-01 15:30","pubTimestamp":1698823800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,美国医药巨头辉瑞CEO Albert Bourla在接受采访时谈到了公司收购癌症药物制造商Seagen的计划。Bourla表示,“我们非常渴望与Seagen联手,”“我们要消灭癌症。”辉瑞计划以430亿美元的价格收购Seagen,Bourla表示,他对该交易将在年底或明年年初完成持\"乐观\"态度。他表示,辉瑞正在与美国联邦贸易委员会讨论批准这笔交易,该交易已经在10月获得了欧盟反垄断机构的无条件批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1018456.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2376602293","title":"辉瑞430亿美元收购Seagen获欧盟无条件批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2376602293","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2376602293?lang=zh_cn&edition=full","pubTime":"2023-10-20 15:35","pubTimestamp":1697787307,"startTime":"0","endTime":"0","summary":"$辉瑞$以430亿美元收购抗癌药物制造商$Seagen$的交易在周四获得欧盟反垄断机构的无条件批准。辉瑞在3月份宣布与Seagen合作时表示,Seagen的产品组合管道将使辉瑞的早期试验性癌症疗法产品线增加一倍。辉瑞CEO Albert Bourla 曾表示,通过430亿美元的收购,该公司将能够“以前所未有的规模”向全世界提供 Seagen 的癌症疗法。3月13日,辉瑞宣布将以430亿美元收购Seagen。在最近的一份报告中,GlobalData预计,到2028年,辉瑞来自Seagen旗下产品的累计总收入预计将达到360亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1008802.html","is_publish_highlight":true,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.seagen.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0782},{"period":"1year","weight":0.1311},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0318},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.2236},{"period":"1year","weight":0.3033},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Seagen Inc.于1997年7月15日在特拉华州成立。该公司是一家全球性生物技术公司,致力于发现,开发和商业化可转化的癌症药物,从而对人们的生活产生重大影响。公司总部位于华盛顿州西雅图市,并在加利福尼亚,加拿大,瑞士和欧盟设有分支机构。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.067078},{"month":2,"riseRate":0.318182,"avgChangeRate":-0.01905},{"month":3,"riseRate":0.590909,"avgChangeRate":0.032822},{"month":4,"riseRate":0.565217,"avgChangeRate":0.032135},{"month":5,"riseRate":0.521739,"avgChangeRate":0.069873},{"month":6,"riseRate":0.652174,"avgChangeRate":0.030835},{"month":7,"riseRate":0.478261,"avgChangeRate":0.024196},{"month":8,"riseRate":0.565217,"avgChangeRate":0.010876},{"month":9,"riseRate":0.73913,"avgChangeRate":0.044385},{"month":10,"riseRate":0.434783,"avgChangeRate":-0.020723},{"month":11,"riseRate":0.608696,"avgChangeRate":0.008771},{"month":12,"riseRate":0.434783,"avgChangeRate":0.00105}],"exchange":"NASDAQ","name":"Seagen","nameEN":"Seagen"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Seagen(SGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Seagen(SGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Seagen,SGEN,Seagen股票,Seagen股票老虎,Seagen股票老虎国际,Seagen行情,Seagen股票行情,Seagen股价,Seagen股市,Seagen股票价格,Seagen股票交易,Seagen股票购买,Seagen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Seagen(SGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Seagen(SGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}